NCT06488118View on ClinicalTrials.gov

Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848)

NARecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 24, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

July 31, 2025

Conditions
Innate ImmunityMucosal ImmunityAsthmaViral Infection
Interventions
DRUG

R848

Inhaled R848 dose ranging from 0.1 to 100 μg/mL

DRUG

Saline

Inhaled Saline control

Trial Locations (1)

CB2 0SL

RECRUITING

NIHR Cambridge Clinical Research Facility, Cambridge

All Listed Sponsors
collaborator

University of Cambridge

OTHER

lead

Akhilesh Jha

OTHER